| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 9BJ85K1J8S |
| InChI Key | PAWIYAYFNXQGAP-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C21H26N6O2 |
| Molecular Weight | 394.48 |
| AlogP | 2.09 |
| Hydrogen Bond Acceptor | 7.0 |
| Hydrogen Bond Donor | 3.0 |
| Number of Rotational Bond | 6.0 |
| Polar Surface Area | 95.31 |
| Molecular species | BASE |
| Aromatic Rings | 3.0 |
| Heavy Atoms | 29.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class I
|
- | 0-4 | 23 | 0-7 | - | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIa
|
- | 1-5 | 28 | 0-7 | - | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | 1-40 | - | 0-4 | - | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IV
|
- | 0 | - | 0-1300 | - | |
|
Unclassified protein
|
- | 5-5 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Lymphoma, T-Cell, Cutaneous | 2 | D016410 | ClinicalTrials |
| Ovarian Neoplasms | 2 | D010051 | ClinicalTrials |
| Lymphoma | 1 | D008223 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 875320-29-9 |
| ChEBI | 94771 |
| ChEMBL | CHEMBL2105763 |
| DrugBank | DB12985 |
| EPA CompTox | DTXSID90236376 |
| FDA SRS | 9BJ85K1J8S |
| Guide to Pharmacology | 7503 |
| PDB | GOK |
| PubChem | 11538455 |
| SureChEMBL | SCHEMBL2360460 |
| ZINC | ZINC000035836133 |